|Bid||20.80 x 800|
|Ask||20.81 x 700|
|Day's Range||20.77 - 20.86|
|52 Week Range||14.27 - 22.83|
|PE Ratio (TTM)||43.47|
|Dividend & Yield||0.33 (1.57%)|
|1y Target Est||N/A|
The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.
A Relative Strength Rating upgrade for Grifols shows improving technical performance.
The Spanish company is the number 2 operator of plasma centers in the world